单药皮下注射贝林妥欧单抗治疗晚期急性淋巴细胞白血病
这项多机构1b期试验扩展阶段纳入29例重度经治的复发/难治性B细胞急性淋巴细胞白血病成人患者,接受皮下注射贝林妥欧单抗两种剂量方案。两周期内250μg/500μg组14例中12例(85.7%)达CR/CRh,500μg/1000μg组13例中12例(92.3%)达CR/CRh;未报告治疗相关4级细胞因子释放综合征或神经事件。
要点
- 250μg/500μg组CR/CRh率为85.7%(12/14),其中75.0%(9/12)MRD阴性。
- 500μg/1000μg组CR/CRh率为92.3%(12/13),全部12例(100.0%)MRD阴性。
- 未报告治疗相关4级细胞因子释放综合征或神经事件,皮下注射耐受良好。
核心结论
- 皮下注射贝林妥欧单抗在重度经治的复发/难治性B细胞急性淋巴细胞白血病成人患者中显示高疗效、高MRD阴性率和可接受的安全性。
研究设计与样本
- 多机构1b期试验(NCT04521231)扩展阶段,纳入重度经治的复发/难治性B细胞急性淋巴细胞白血病成人患者。
- 29例患者接受治疗:250μg/500μg剂量组14例,500μg/1000μg剂量组13例;排除2例不合格患者的数据。
- 主要终点为两周期内完全缓解/伴部分血液学恢复的完全缓解(CR/CRh)。
主要发现
- 250μg/500μg组14例中12例(85.7%)达CR/CRh,其中9例(75.0%)MRD阴性(<10⁻⁴白血病原始细胞)。
- 500μg/1000μg组13例中12例(92.3%)达CR/CRh,全部12例(100.0%)MRD阴性。
- 未报告治疗相关4级细胞因子释放综合征或神经事件;所有治疗相关3级细胞因子释放综合征和神经事件经标准治疗、中断或停药后缓解。
关键数值与推荐
- 250μg/500μg方案:第1周250μg每日一次,此后500μg每周三次。
- 500μg/1000μg方案:第1周500μg每日一次,此后1000μg每周三次。
- CR/CRh:250μg/500μg组85.7%(12/14)vs 500μg/1000μg组92.3%(12/13)。
- MRD阴性(<10⁻⁴):250μg/500μg组75.0%(9/12)vs 500μg/1000μg组100.0%(12/12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi-institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg). The primary endpoint was complete remission/complete remission with partial hematologic recovery (CR/CRh) within two cycles. At the data cutoff of September 15, 2023, 29 patients were treated: 14 at the 250 μg/500 μg dose and 13 at 500 μg/1000 μg dose. Data from two ineligible patients were excluded. At the end of two cycles, 12 of 14 patients (85.7%) from the 250 μg/500 μg dose achieved CR/CRh of which nine patients (75.0%) were negative for measurable residual disease (MRD; <10-4 leukemic blasts). At the 500 μg/1000 μg dose, 12 of 13 patients (92.3%) achieved CR/CRh; all 12 patients (100.0%) were MRD-negative. No treatment-related grade 4 cytokine release syndrome (CRS) or neurologic events (NEs) were reported. SC injections were well tolerated and all treatment-related grade 3 CRS and NEs responded to standard-of-care management, interruption, or discontinuation. Treatment with SC blinatumomab resulted in high efficacy, with high MRD-negativity rates and acceptable safety profile in heavily pretreated adults with R/R B-ALL.
引用
- Jabbour E, Zugmaier G, Agrawal V, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024. PMID: 38317420. doi:10.1002/ajh.27227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。